SYR-472 Open-label Study

To evaluate the efficacy and safety of treatment with SYR-472 in diabetic patients.

Completed

Looking for future studies?

Key information

Conditions

Diabetes Mellitus Endocrine System Diseases Glucose Metabolism Disorders Metabolic Diseases Nutritional and Metabolic Diseases

Age range

20 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Suita-shi, Osaka, Japan

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

-1. The participant is judged to be capable of understanding and complying with protocol requirements by the investigator or subinvestigator.

The participant can sign and date a written, informed consent form prior to the initiation of any study procedures.

Exclusion criteria

-1. The participant has concurrent serious cardiac disease, serious cerebrovascular disorder, or serious pancreatic or hematological disease

. 2. The participant is assessed to be ineligible for the study by the investigator or subinvestigator.

Treatment and study plan

SYR-472

Drug

Primary outcomes

Blood Glucose

Time frame: 7 days

Blood Glucose

Sponsors and collaborators

Lead sponsor

Takeda

Industry

Registry information

Important dates

Study start: 2013
Primary completion: 2013
Study completion: 2013
First posted: Dec 18, 2012
Registry last updated: Dec 11, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed